Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

In vitro characterization of MOD-5014, a novel long-acting carboxy-terminal peptide (CTP)-modified activated FVII.

Bar-Ilan A, Livnat T, Hoffmann M, Binder L, Zakar M, Guy R, Felikman Y, Moschcovich L, Shenkman B, Monroe D, Hershkovitz O, Kenet G, Hart G.

Haemophilia. 2018 May;24(3):477-486. doi: 10.1111/hae.13428. Epub 2018 Mar 14.

PMID:
29537116
2.

Pharmacokinetics, Pharmacodynamics, and Safety of a Long-Acting Human Growth Hormone (MOD-4023) in Healthy Japanese and Caucasian Adults.

Kramer WG, Jaron-Mendelson M, Koren R, Hershkovitz O, Hart G.

Clin Pharmacol Drug Dev. 2018 Jun;7(5):554-563. doi: 10.1002/cpdd.414. Epub 2017 Nov 14.

PMID:
29136343
3.

Long-Acting C-Terminal Peptide-Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children.

Zelinska N, Iotova V, Skorodok J, Malievsky O, Peterkova V, Samsonova L, Rosenfeld RG, Zadik Z, Jaron-Mendelson M, Koren R, Amitzi L, Raduk D, Hershkovitz O, Hart G.

J Clin Endocrinol Metab. 2017 May 1;102(5):1578-1587. doi: 10.1210/jc.2016-3547.

PMID:
28323965
4.

MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults.

Strasburger CJ, Vanuga P, Payer J, Pfeifer M, Popovic V, Bajnok L, Góth M, Olšovská V, Trejbalová L, Vadasz J, Fima E, Koren R, Amitzi L, Bidlingmaier M, Hershkovitz O, Hart G, Biller BM.

Eur J Endocrinol. 2017 Mar;176(3):283-294. doi: 10.1530/EJE-16-0748. Epub 2016 Dec 8.

5.

In Vitro and in Vivo Characterization of MOD-4023, a Long-Acting Carboxy-Terminal Peptide (CTP)-Modified Human Growth Hormone.

Hershkovitz O, Bar-Ilan A, Guy R, Felikman Y, Moschcovich L, Hwa V, Rosenfeld RG, Fima E, Hart G.

Mol Pharm. 2016 Feb 1;13(2):631-9. doi: 10.1021/acs.molpharmaceut.5b00868. Epub 2016 Jan 18.

PMID:
26713839
6.

Genome-wide siRNA screen reveals a new cellular partner of NK cell receptor KIR2DL4: heparan sulfate directly modulates KIR2DL4-mediated responses.

Brusilovsky M, Cordoba M, Rosental B, Hershkovitz O, Andrake MD, Pecherskaya A, Einarson MB, Zhou Y, Braiman A, Campbell KS, Porgador A.

J Immunol. 2013 Nov 15;191(10):5256-67. doi: 10.4049/jimmunol.1302079. Epub 2013 Oct 14.

7.

[Atypical femoral fractures in long-term osteoporotic treatment with bisphosphonates].

Thein R, Tenenbaum S, Chechick O, Hershkovitz O, Chechik A, Caspi I.

Harefuah. 2012 Sep;151(9):532-6, 555. Hebrew.

PMID:
23367748
8.

Upregulation of MHC class I expression following dengue virus infection: the mechanism at the promoter level.

Yossef R, Rosental B, Appel MY, Hershkovitz O, Porgador A.

Expert Rev Anti Infect Ther. 2012 Mar;10(3):285-7. doi: 10.1586/eri.12.7.

PMID:
22397562
9.

Generating NK cell receptor-Fc chimera proteins from 293T cells and considerations of appropriate glycosylation.

Zilka A, Mendelson M, Rosental B, Hershkovitz O, Porgador A.

Methods Mol Biol. 2010;612:275-83. doi: 10.1007/978-1-60761-362-6_18.

PMID:
20033647
10.

The activating receptor NKp46 is essential for the development of type 1 diabetes.

Gur C, Porgador A, Elboim M, Gazit R, Mizrahi S, Stern-Ginossar N, Achdout H, Ghadially H, Dor Y, Nir T, Doviner V, Hershkovitz O, Mendelson M, Naparstek Y, Mandelboim O.

Nat Immunol. 2010 Feb;11(2):121-8. doi: 10.1038/ni.1834. Epub 2009 Dec 20.

PMID:
20023661
11.

NKp44 receptor mediates interaction of the envelope glycoproteins from the West Nile and dengue viruses with NK cells.

Hershkovitz O, Rosental B, Rosenberg LA, Navarro-Sanchez ME, Jivov S, Zilka A, Gershoni-Yahalom O, Brient-Litzler E, Bedouelle H, Ho JW, Campbell KS, Rager-Zisman B, Despres P, Porgador A.

J Immunol. 2009 Aug 15;183(4):2610-21. doi: 10.4049/jimmunol.0802806. Epub 2009 Jul 27.

12.

Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate/heparin sequences.

Hecht ML, Rosental B, Horlacher T, Hershkovitz O, De Paz JL, Noti C, Schauer S, Porgador A, Seeberger PH.

J Proteome Res. 2009 Feb;8(2):712-20. doi: 10.1021/pr800747c.

PMID:
19196184
13.

Dengue virus replicon expressing the nonstructural proteins suffices to enhance membrane expression of HLA class I and inhibit lysis by human NK cells.

Hershkovitz O, Zilka A, Bar-Ilan A, Abutbul S, Davidson A, Mazzon M, Kümmerer BM, Monsoengo A, Jacobs M, Porgador A.

J Virol. 2008 Aug;82(15):7666-76. doi: 10.1128/JVI.02274-07. Epub 2008 May 28.

14.

H5-type influenza virus hemagglutinin is functionally recognized by the natural killer-activating receptor NKp44.

Ho JW, Hershkovitz O, Peiris M, Zilka A, Bar-Ilan A, Nal B, Chu K, Kudelko M, Kam YW, Achdout H, Mandelboim M, Altmeyer R, Mandelboim O, Bruzzone R, Porgador A.

J Virol. 2008 Feb;82(4):2028-32. Epub 2007 Dec 12.

15.

Altered glycosylation of recombinant NKp30 hampers binding to heparan sulfate: a lesson for the use of recombinant immunoreceptors as an immunological tool.

Hershkovitz O, Jarahian M, Zilka A, Bar-Ilan A, Landau G, Jivov S, Tekoah Y, Glicklis R, Gallagher JT, Hoffmann SC, Zer H, Mandelboim O, Watzl C, Momburg F, Porgador A.

Glycobiology. 2008 Jan;18(1):28-41. Epub 2007 Nov 15.

PMID:
18006589
16.

Expression of ligands to NKp46 in benign and malignant melanocytes.

Cagnano E, Hershkovitz O, Zilka A, Bar-Ilan A, Golder A, Sion-Vardy N, Bogdanov-Berezovsky A, Mandelboim O, Benharroch D, Porgador A.

J Invest Dermatol. 2008 Apr;128(4):972-9. Epub 2007 Nov 1.

17.

Characterization of the recognition of tumor cells by the natural cytotoxicity receptor, NKp44.

Hershkovitz O, Jivov S, Bloushtain N, Zilka A, Landau G, Bar-Ilan A, Lichtenstein RG, Campbell KS, van Kuppevelt TH, Porgador A.

Biochemistry. 2007 Jun 26;46(25):7426-36. Epub 2007 May 31.

PMID:
17536787
18.

Characterization of the heparin/heparan sulfate binding site of the natural cytotoxicity receptor NKp46.

Zilka A, Landau G, Hershkovitz O, Bloushtain N, Bar-Ilan A, Benchetrit F, Fima E, van Kuppevelt TH, Gallagher JT, Elgavish S, Porgador A.

Biochemistry. 2005 Nov 8;44(44):14477-85.

PMID:
16262248
19.

Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46.

Bloushtain N, Qimron U, Bar-Ilan A, Hershkovitz O, Gazit R, Fima E, Korc M, Vlodavsky I, Bovin NV, Porgador A.

J Immunol. 2004 Aug 15;173(4):2392-401.

Supplemental Content

Loading ...
Support Center